Maxim affirmed Inovio Pharma (Nasdaq: INO) with a Buy rating and $14 price target following Q4 results and acquisition of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Inovio Pharma (INO) to Acquire Assets of Bioject Medical Technologies for $5.5MMarch 14, 2016 8:05 AM Inovio Pharmaceuticals Acquires Needle-Free Injection Technology to Advance Strategy for Next-Generation VaccinesMarch 14, 2016 8:01 AM Inovio Pharmaceuticals Reports 2015 Fourth Quarter and Year End Financial ResultsMarch 14, 2016 6:30 AM Inovio Pharma (INO) Posts Q4 Loss of 25c/ShareMarch 14, 2016 6:13 AM